派林生物人凝血酶临床试验获受理

Core Viewpoint - The company has received approval for a clinical trial of its human thrombin drug, which is expected to enhance its product line and overall competitiveness in the long term [1] Group 1: Company Announcement - The company announced that its wholly-owned subsidiary, Guangdong Shuanglin Biological Pharmaceutical Co., Ltd., has received the acceptance notice for the clinical trial registration of human thrombin from the National Medical Products Administration [1] - The approval for the clinical trial will not impact the company's current performance but is expected to enrich the product line in the long term [1] Group 2: Strategic Implications - The new product will help optimize the company's product structure and improve the comprehensive utilization rate of raw plasma, thereby enhancing profitability [1] - This development is anticipated to further strengthen the company's core competitiveness in the market [1]